Table 2.

Studies illustrating prognostically important geriatric deficits in older patients undergoing alloHCT

Study	N	Age, median (range), y	Study design disease	Impairment in GA domains with impact on outcomes
				Comorbidity	Function	Mobility	Cognition	Medication	Frailty scale
Muffly et al. (2014)35	203	58 (54-63)	Prospective, single-center pilot study All diseases	NRM ↑ OS ↓	NRM ↑ OS ↓	OS ↓
Deschler et al. (2018)36	106	66 (60-78)	Prospective, single-center trial Myeloid neoplasms	NRM ↑ PFS ↓	OS ↓ PFS ↓	OS ↓
Huang et al. (2020)37	148	62 (50-76)	Prospective, single-center pilot study All diseases		OS ↓ PFS ↓ NRM ↑ Toxicities ↑
Pamukcuoglu et al. (2019)40	52	59 (40-73)	Prospective, single-center pilot study All diseases						OS ↓ Toxicities ↑
Salas et al. (2021)41	168	58 (19-77)	Prospective, single-center pilot study All diseases			NRM ↑ OS ↓			NRM ↑
Olin et al. (2020)38	330	63 (50-77)	Multicenter, CIBMTR registry All diseases	NRM ↑			NRM ↑ OS ↓
Polverelli et al. (2020)42	228	64 (60-76)	Two-center retrospective study						NRM ↑ OS ↓
Lin et al. (2020)39	457	66 (60-79)	Single-center, retrospective study	NRM ↑	NRM ↑ OS ↓ PFS ↓
Bhargava et al. (2020)43	114	68 (65-75)	Single-center, retrospective study					Toxicities ↑ OS ↓
Sugidono et al. (2021)44	148	62 (50-76)	Single-center, retrospective study					OS ↓

NRM, nonrelapse mortality; PFS, progression-free survival.